MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has announced the issuance of 102,044 new shares of common stock as a result of share options exercises and vesting of restricted stock units, bringing the total issued stock capital to 104,824,124 shares as of June 30, 2024. This update provides shareholders with the denominator needed for calculating changes in their ownership stake. The company, a leader in cell-engineering technologies, continues to support the development of next-generation cell-based therapeutics through its innovative platforms.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
